Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (241)	1/27/1998 8:44:00 PM
From: David Bogdanoff	Read Replies (2) \| Respond to of 507

RS: Thanks for informative link. Slightly puzzled by the story; it states that the pertactin component is changed in the strain; presumably the immune system does not recognize the modified pertactin protein and so is not activated against it. Then, according to the news item, vaccines which immunity to pertactin and other proteins would be protective. I understand the why a vaccine protective against other proteins should work, but it seems to me that one that acts against a normal pertactin protein would be lack effectiveness; in fact, the news item as much as says this. So how would a vaccine with a pertactin component offer protection against the mutant strain? Something doesn't add up here. It seems to me that a vaccine with components against proteins other than pertactin would be more effective against the mutant strain. David